GNMSF logo

Genmab A/S (GNMSF) Aktienanalyse

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist Genmab A/S (GNMSF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 55/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 15. März 2026
55/100 KI-Bewertung

Genmab A/S (GNMSF) Gesundheitswesen & Pipeline-Uebersicht

CEOJan van de Winkel
Mitarbeiter2638
HauptsitzCopenhagen, DK
IPO-Jahr2010

Genmab A/S, a Danish biotechnology firm, focuses on developing innovative antibody therapeutics for cancer and other diseases. With a diverse portfolio of marketed products like DARZALEX and a robust pipeline, Genmab competes in the global biotechnology market, leveraging strategic collaborations to expand its reach and development capabilities.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 15. März 2026

Investmentthese

Genmab A/S presents a notable research candidate within the biotechnology sector, driven by its innovative antibody therapeutics platform and strong pipeline. The company's marketed products, including DARZALEX, generate significant revenue, contributing to a profit margin of 16.7% and a gross margin of 93.6%. Growth catalysts include the continued expansion of DARZALEX in multiple myeloma and other indications, as well as the potential approval and commercialization of pipeline assets like epcoritamab. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. With a market capitalization of $16.97 billion and a P/E ratio of 25.88, Genmab's valuation reflects its growth potential and established market position. The company's beta of 0.75 suggests lower volatility compared to the overall market.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $16.97 billion, reflecting investor confidence in its antibody therapeutics platform.
  • Profit margin of 16.7%, indicating efficient operations and strong profitability.
  • Gross margin of 93.6%, highlighting the high value of its products and effective cost management.
  • P/E ratio of 25.88, suggesting a premium valuation based on future growth expectations.
  • Beta of 0.75, indicating lower volatility compared to the broader market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Innovative antibody therapeutics platform.
  • Strong pipeline of products in development.
  • Established market presence with marketed products.
  • Strategic collaborations with leading pharmaceutical companies.

Schwaechen

  • Reliance on key products like DARZALEX.
  • High R&D spending.
  • Dependence on collaborations for commercialization.
  • Exposure to clinical trial risks.

Katalysatoren

  • Ongoing: Continued expansion of DARZALEX in multiple myeloma and other indications.
  • Upcoming: Potential approval and commercialization of epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
  • Ongoing: Advancement of pipeline assets through clinical trials.
  • Ongoing: Strategic collaborations with leading pharmaceutical and biotechnology companies.
  • Upcoming: Potential for geographic expansion into new markets.

Risiken

  • Potential: Clinical trial failures.
  • Potential: Regulatory hurdles and delays.
  • Ongoing: Competition from other biotechnology companies.
  • Potential: Patent expirations.
  • Ongoing: Reliance on key products like DARZALEX.

Wachstumschancen

  • Expansion of DARZALEX: DARZALEX, Genmab's leading product for multiple myeloma, has significant growth potential through label expansions and increased market penetration. The global multiple myeloma market is projected to reach $37.5 billion by 2028, providing a substantial opportunity for Genmab to increase its revenue. The company is actively pursuing clinical trials to evaluate DARZALEX in new indications and combinations, which could further drive growth.
  • Commercialization of Epcoritamab: Epcoritamab, a bispecific antibody being developed in collaboration with AbbVie, has the potential to become a significant growth driver for Genmab. Epcoritamab targets relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The market for lymphoma treatments is expected to grow, offering a substantial opportunity for Epcoritamab upon regulatory approval. The drug is currently under review by regulatory agencies.
  • Advancement of Pipeline Assets: Genmab has a robust pipeline of antibody therapeutics in various stages of development, targeting a range of diseases. The successful advancement and commercialization of these pipeline assets could significantly expand Genmab's revenue base and market presence. The company's pipeline includes products such as Teclistamab, Camidanlumab tesirine, and several other preclinical and clinical programs.
  • Strategic Collaborations: Genmab's strategic collaborations with leading pharmaceutical and biotechnology companies provide access to external expertise, resources, and markets. These collaborations can accelerate the development and commercialization of Genmab's antibody therapeutics and expand its global reach. The company's collaborations with AbbVie, Janssen, and other partners are expected to contribute to its long-term growth.
  • Geographic Expansion: Genmab has the opportunity to expand its geographic presence and market its products in new regions. The company currently operates primarily in Denmark, but its products are marketed globally through partnerships. Expanding into new markets, such as Asia and Latin America, could significantly increase Genmab's revenue and market share. The company may need to establish local infrastructure and partnerships to succeed in these new markets.

Chancen

  • Expansion of DARZALEX into new indications.
  • Commercialization of pipeline assets like epcoritamab.
  • Geographic expansion into new markets.
  • Strategic acquisitions and partnerships.

Risiken

  • Competition from other biotechnology companies.
  • Regulatory hurdles and delays.
  • Clinical trial failures.
  • Patent expirations.

Wettbewerbsvorteile

  • Proprietary antibody therapeutics platform.
  • Strong pipeline of innovative products.
  • Strategic collaborations with leading pharmaceutical companies.
  • Established market presence with marketed products like DARZALEX.

Ueber GNMSF

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab A/S is a biotechnology company dedicated to creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. The company's initial focus was on developing human monoclonal antibodies, and it has since expanded its portfolio through strategic collaborations and internal research and development efforts. Genmab's marketed products include DARZALEX (daratumumab) for multiple myeloma (MM), teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Genmab's pipeline includes a range of products in various stages of development, targeting hematological malignancies and solid tumors. These include GEN1047, tisotumab vedotin (co-developed with Seagen Inc.), DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, Epcoritamab (developed in collaboration with AbbVie), HexaBody-CD38, and DuoHexaBody-CD37. The company also has several products in Phase 2 clinical trials, such as Teclistamab, Camidanlumab tesirine, JNJ-64007957, JNJ-64407564, PRV-015, Mim8, and Lu AF82422. Genmab has established collaborations with several leading pharmaceutical and biotechnology companies, including CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. These collaborations enable Genmab to leverage external expertise and resources to accelerate the development and commercialization of its antibody therapeutics. Genmab operates primarily in Denmark, with a global reach through its partnerships and marketed products.

Was das Unternehmen tut

  • Develops antibody therapeutics for cancer and other diseases.
  • Markets DARZALEX for the treatment of multiple myeloma (MM).
  • Markets teprotumumab for the treatment of thyroid eye disease.
  • Markets ofatumurnab for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis.
  • Markets Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
  • Develops products for treating hematological malignancies and solid tumors.
  • Collaborates with other companies to co-develop and commercialize antibody therapeutics.

Geschaeftsmodell

  • Develops and commercializes antibody therapeutics.
  • Generates revenue through product sales and royalties.
  • Collaborates with other companies to co-develop and commercialize products.
  • Out-licenses its technology and products to generate revenue.

Branchenkontext

Genmab A/S operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The global biotechnology market is experiencing substantial growth, driven by increasing demand for novel therapeutics, advancements in antibody engineering, and a growing prevalence of cancer and other diseases. Genmab competes with other biotechnology companies, including ALPMF (Alphamab Oncology), ALPMY (Alphamab Oncology), BMXXY (BioMaxx Pharmaceuticals), GIKLY (Ginkgo Bioworks Holdings), and IVBXF (Invex Therapeutics), in the development and commercialization of antibody therapeutics. The company's strategic collaborations and differentiated technology platform position it favorably within the industry.

Wichtige Kunden

  • Patients with cancer and other diseases.
  • Hospitals and clinics.
  • Pharmaceutical companies.
  • Healthcare providers.
KI-Zuversicht: 71% Aktualisiert: 15. März 2026

Finanzdaten

Chart & Info

Genmab A/S (GNMSF) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GNMSF.

Kursziele

Wall-Street-Kurszielanalyse fuer GNMSF.

MoonshotScore

55/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von GNMSF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Klassifizierung

Sektor Healthcare Branche Biotechnology

Aktuelle Nachrichten

Fuehrung: Jan van de Winkel

CEO

Jan van de Winkel is the CEO of Genmab A/S. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions and has a strong track record in drug development and commercialization. Van de Winkel's expertise spans from early-stage research to late-stage clinical development and market access. He is known for his strategic vision and ability to drive innovation within the biotechnology sector.

Erfolgsbilanz: Under Jan van de Winkel's leadership, Genmab A/S has achieved significant milestones, including the successful development and commercialization of DARZALEX and other antibody therapeutics. He has overseen the expansion of Genmab's pipeline and the establishment of strategic collaborations with leading pharmaceutical companies. Van de Winkel's leadership has been instrumental in driving Genmab's growth and establishing its position as a leading biotechnology company.

GNMSF OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that Genmab A/S (GNMSF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of stringent listing requirements and regulatory oversight.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity for GNMSF on the OTC market is likely limited, which can result in wider bid-ask spreads and greater price volatility. Trading volume may be thin, making it difficult to buy or sell large quantities of shares without significantly impacting the price. Investors should exercise caution and be aware of the potential challenges in executing trades efficiently.
OTC-Risikofaktoren:
  • Limited financial disclosure, making it difficult to assess the company's financial health.
  • Lower liquidity, leading to wider bid-ask spreads and greater price volatility.
  • Less regulatory oversight compared to companies listed on major exchanges.
  • Potential for fraud or manipulation due to the lack of stringent listing requirements.
  • Higher risk of delisting or going out of business.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Review the company's legal and regulatory compliance.
  • Evaluate the company's liquidity and trading volume.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Legitimitaetssignale:
  • Established partnerships with reputable pharmaceutical companies.
  • Marketed products with regulatory approvals.
  • Experienced management team with a track record in the biotechnology industry.
  • Presence in a regulated industry (healthcare).
  • Publicly available information and press releases.

Was Anleger ueber Genmab A/S (GNMSF) wissen wollen

What are the key factors to evaluate for GNMSF?

Genmab A/S (GNMSF) currently holds an AI score of 55/100, indicating moderate score. Key strength: Innovative antibody therapeutics platform.. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.

How frequently does GNMSF data refresh on this page?

GNMSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven GNMSF's recent stock price performance?

Recent price movement in Genmab A/S (GNMSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative antibody therapeutics platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider GNMSF overvalued or undervalued right now?

Determining whether Genmab A/S (GNMSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying GNMSF?

Before investing in Genmab A/S (GNMSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding GNMSF to a portfolio?

Potential reasons to consider Genmab A/S (GNMSF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative antibody therapeutics platform.. Additionally: Strong pipeline of products in development.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of GNMSF?

Yes, most major brokerages offer fractional shares of Genmab A/S (GNMSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track GNMSF's earnings and financial reports?

Genmab A/S (GNMSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GNMSF earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • AI analysis pending for GNMSF.
  • OTC market data may be less reliable than exchange-listed data.
Datenquellen

Popular Stocks